Home World News Alpha cognition protects additional American patent for junway (benzalantamine) in the treatment...

World News

Alpha cognition protects additional American patent for junway (benzalantamine) in the treatment of mild and moderate Alzheimer’s disease

February 12, 2025

Vancouver – Alpha Cognition Inc. (Nastag: Acog) . “Plated pills for the release of benzalantamin’s pH-releases.”

Article content

The newly supplied patent is a combination of tablet formulas of the Alpha intelligence, strengthening the intellectual property portfolio of the alpha intelligence, and further strengthens the company’s current patent protection. With this approval, Junwille has patent protection in the United States by 2044, which supports the company’s long -term growth strategy when preparing for commercialization.

Article content

“This patent approval underlines the innovation of Junway and improves our ability to provide a different treatment option for patients with mild and mild Alzheimer’s disease,” said Michael McBaden, CEO Michael McBaden, CEO of Alba Cognis. “The time of this milestone is significant because it is in line with our planned US release in this quarter. We are well established to enhance the efficiency of Junway, with extended patent protection, and continue to improve solutions for Alzheimer’s victims.”

Zunveyl refers to a new approach to the treatment of Alzheimer’s treatment designed to improve the effects of the patient through optimal drug distribution. Q1 2025 is available in pharmacies throughout the country by drug.

About alpha cognition.

Alpha Cognition Inc. It is dedicated to develop treatment for patients with neurodegenerative diseases such as a medical phase, a biological pharmacist, Alzheimer’s disease and mild traumatic brain injury (“MTPI”), which is not currently recognized treatment options.

For more information, please visit www.alphacognition.com.

Reports to see forward

This news output contains perspective orientations within the meaning of bond laws that are applicable. In addition to the reports of the historical fact, any information in the news release may be a predecessor report that reflects the current ideas of the company and the unknown and unknown and unknown risks, uncertainty, assumptions and other factors that can cause real causes Are materially distinguished from the information expressed or marked by statements. In some cases, “May,” “May,” “Option,” “Can,” “Can,” “To Do,” “To Expect,” “Aim,” “Planning” , “” Expectation, “” assessment, “” assessment, “” prediction, “” Plan, “” Plan, “” Goal, “” Search, ” , Or other comparable words that are intended to identify statements about the future. These perspective reports are subject to some risks, in which our ability to mobilize our plans for commercialization of Junwayil, our ability to mobilize our plans, Junwayil’s performance and tolerance risks, Zunveyl’s security on the security of Zunveyl’s security, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, risks, Junwail Related risks, business production, distribution, marketing and sales -related risks, product responsible risks and other risks as being filed with Canadian Company Regulatory Officers and Available www.sedar.com And filing the United States and Transaction Authority (“SEC”), including the SEC filed in the SEC on November 6, including the risk factors under the topic “Risk Factors” in the company’s S -1/A registration report , Including those risk factors, that risk factors, 2024 and available www.sec.gov. These perspective statements only speak according to the date of this news release, and for any reason the company has not obligated or renovated or renewed any of the reports, except for the need for new information in the future.